<unk>  is an immunosuppresive drug; it binds to CD20, which is selectively made by B cells, and when<unk>  binds to CD20 it kills B cells by causing antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.
Ocrelizumab
Risankizumab
Ibalizumab
Theralizumab
Brolucizumab
Atezolizumab
Inebilizumab
Etaracizumab